Mackenzie Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.32M	Buy	243,416 +92,688	+61%	+$720K	﹤0.01%	891
2025 Q4	$1.15M	Buy	150,728 +21,411	+17%	+$155K	﹤0.01%	1018
2025 Q3	$982K	Buy	129,317 +22,834	+21%	+$190K	﹤0.01%	1067
2025 Q2	$954K	Sell	106,483 -9,775	-8%	-$91K	﹤0.01%	1020
2025 Q1	$872K	Buy	116,258 +31,596	+37%	+$255K	﹤0.01%	1017
2024 Q4	$637K	Buy	84,662 +55,535	+191%	+$422K	﹤0.01%	1075
2024 Q3	$221K	Buy	29,127 +1,214	+4%	+$9.23K	﹤0.01%	1340
2024 Q2	$173K	Sell	27,913 -4,344	-13%	-$24K	﹤0.01%	1367
2024 Q1	$164K	Buy	32,257 +8,818	+38%	+$49.6K	﹤0.01%	1374
2023 Q4	$140K	Buy	23,439 +10,026	+75%	+$58.1K	﹤0.01%	1375
2023 Q3	$86.1K	Sell	13,413 -38,669	-74%	-$278K	﹤0.01%	1363
2023 Q2	$367K	Sell	52,082 -6,798	-12%	-$54.6K	﹤0.01%	1110
2023 Q1	$491K	Buy	58,880 +37,520	+176%	+$361K	﹤0.01%	1033
2022 Q4	$245K	Sell	21,360 -31,227	-59%	-$389K	﹤0.01%	1155
2022 Q3	$663K	Buy	52,587 +28,931	+122%	+$372K	﹤0.01%	878
2022 Q2	$250K	Buy	23,656 +5,850	+33%	+$60.3K	﹤0.01%	1172
2022 Q1	$290K	Buy	+17,806	New	+$286K	﹤0.01%	1133
2021 Q4	–	Sell	-10,423	Closed	-$150K	–	1439
2021 Q3	$150K	Buy	+10,423	New	+$164K	﹤0.01%	1354